Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia : a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology
© 2024. The Author(s)..
Although granulocyte colony-stimulating factor (G-CSF) reduces the incidence, duration, and severity of neutropenia, its prophylactic use for acute myeloid leukemia (AML) remains controversial due to a theoretically increased risk of relapse. The present study investigated the effects of G-CSF as primary prophylaxis for AML with remission induction therapy. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two reviewers. A qualitative analysis of pooled data was conducted, and the risk ratio with corresponding confidence intervals was calculated in the meta-analysis and summarized. Sixteen studies were included in the qualitative analysis, nine of which were examined in the meta-analysis. Although G-CSF significantly shortened the duration of neutropenia, primary prophylaxis with G-CSF did not correlate with infection-related mortality. Moreover, primary prophylaxis with G-CSF did not affect disease progression/recurrence, overall survival, or adverse events, such as musculoskeletal pain. However, evidence to support or discourage the use of G-CSF as primary prophylaxis for adult AML patients with induction therapy remains limited. Therefore, the use of G-CSF as primary prophylaxis can be considered for adult AML patients with remission induction therapy who are at a high risk of infectious complications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
International journal of clinical oncology - 29(2024), 5 vom: 15. Apr., Seite 535-544 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maeda, Tomoya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
143011-72-7 |
|---|
| Anmerkungen: |
Date Completed 24.04.2024 Date Revised 27.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10147-023-02465-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369842642 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369842642 | ||
| 003 | DE-627 | ||
| 005 | 20240427232144.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240318s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10147-023-02465-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1390.xml |
| 035 | |a (DE-627)NLM369842642 | ||
| 035 | |a (NLM)38494578 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maeda, Tomoya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia |b a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.04.2024 | ||
| 500 | |a Date Revised 27.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Although granulocyte colony-stimulating factor (G-CSF) reduces the incidence, duration, and severity of neutropenia, its prophylactic use for acute myeloid leukemia (AML) remains controversial due to a theoretically increased risk of relapse. The present study investigated the effects of G-CSF as primary prophylaxis for AML with remission induction therapy. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two reviewers. A qualitative analysis of pooled data was conducted, and the risk ratio with corresponding confidence intervals was calculated in the meta-analysis and summarized. Sixteen studies were included in the qualitative analysis, nine of which were examined in the meta-analysis. Although G-CSF significantly shortened the duration of neutropenia, primary prophylaxis with G-CSF did not correlate with infection-related mortality. Moreover, primary prophylaxis with G-CSF did not affect disease progression/recurrence, overall survival, or adverse events, such as musculoskeletal pain. However, evidence to support or discourage the use of G-CSF as primary prophylaxis for adult AML patients with induction therapy remains limited. Therefore, the use of G-CSF as primary prophylaxis can be considered for adult AML patients with remission induction therapy who are at a high risk of infectious complications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a AML | |
| 650 | 4 | |a Adults | |
| 650 | 4 | |a G-CSF | |
| 650 | 4 | |a Induction therapy | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Neutropenia | |
| 650 | 7 | |a Granulocyte Colony-Stimulating Factor |2 NLM | |
| 650 | 7 | |a 143011-72-7 |2 NLM | |
| 700 | 1 | |a Najima, Yuho |e verfasserin |4 aut | |
| 700 | 1 | |a Kamiyama, Yutaro |e verfasserin |4 aut | |
| 700 | 1 | |a Nakao, Shinji |e verfasserin |4 aut | |
| 700 | 1 | |a Ozaki, Yukinori |e verfasserin |4 aut | |
| 700 | 1 | |a Nishio, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuchihashi, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Ichihara, Eiki |e verfasserin |4 aut | |
| 700 | 1 | |a Miumra, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Endo, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Maruyama, Dai |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshinami, Tatsuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Susumu, Nobuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Takekuma, Munetaka |e verfasserin |4 aut | |
| 700 | 1 | |a Motohashi, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Mamoru |e verfasserin |4 aut | |
| 700 | 1 | |a Baba, Eishi |e verfasserin |4 aut | |
| 700 | 1 | |a Ochi, Nobuaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kubo, Toshio |e verfasserin |4 aut | |
| 700 | 1 | |a Uchino, Keita |e verfasserin |4 aut | |
| 700 | 1 | |a Kimura, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tamura, Shinobu |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimoto, Hitomi |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Yasuhisa |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Takano, Toshimi |e verfasserin |4 aut | |
| 700 | 1 | |a Yano, Shingo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of clinical oncology |d 1997 |g 29(2024), 5 vom: 15. Apr., Seite 535-544 |w (DE-627)NLM095566163 |x 1437-7772 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:5 |g day:15 |g month:04 |g pages:535-544 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10147-023-02465-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 5 |b 15 |c 04 |h 535-544 | ||